+966 568813716 [email protected]

Medical Students

Home / E-Lessons / Archive by category "Medical Students" (Page 12)
03
Dec
2016
Modafinil (Provigil®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Modafinil (US brand name Provigil® and generic) is a wakefulness promoting agent. Here is key information about this medication. FDA-approved indications To improve wakefulness in adult patients with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD) Dosage 1. Adults Narcolepsy or OSA: 200 mg […]

Read More

03
Dec
2016
How to Screen for Sleep Apnea
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

    To screen for Obstructive Sleep Apnea, we need to check for multiple factors. The STOP-Bang questionnaire looks at these multiple factors. A link to information about the questionnaire is provided below.       1. Snoring Ask the patient and the person who sleeps […]

Read More

03
Dec
2016
New warning about aripiprazole
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

The FDA issued a warning on May 3, 2016 about aripiprazole stating that “compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of aripiprazole (Abilify®, Abilify Maintena®, Aristada®, and generics). These uncontrollable urges were reported to have […]

Read More

03
Dec
2016
Olanzapine (Zyprexa®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Olanzapine (US brand name Zyprexa® and generic) is a second-generation (atypical) antipsychotic. Here is basic information about this medication. FDA-approved indications 1. As oral formulation for: a. Schizophrenia in adults and adolescents b. Manic or mixed episodes associated with bipolar I disorder in adults and adolescents […]

Read More

03
Dec
2016
Paliperidone (Invega®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Paliperidone extended-release (US brand name Invega® and generic) is a second-generation (“atypical”) antipsychotic. FDA-approved indications 1. Treatment of schizophrenia in adults and adolescents (ages 12-17) 2. Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. Dosage A. Schizophrenia […]

Read More

03
Dec
2016
Risperidone (Risperdal®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Risperidone (US brand name Risperdal® and generic) is a second-generation (“atypical”) antipsychotic. Here is basic information about this medication. FDA-approved indications 1. Treatment of schizophrenia 2. As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I […]

Read More

03
Dec
2016
Risperidone long-acting (Risperdal Consta®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Risperdal Consta® is a long-acting injectable formulation of risperidone, a second-generation (“atypical”) antipsychotic. Here is basic information about this medication. FDA-Approved Indications Schizophrenia Monotherapy for the maintenance treatment of Bipolar I Disorder Adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder. […]

Read More

03
Dec
2016
3-month paliperidone palmitate (Invega Trinza®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Paliperidone palmitate (Invega Trinza®) is an extended-release injectable second-generation (“atypical”) antipsychotic which can be administered once every 3 months. Here is basic information about this medication. FDA-Approved Indication Schizophrenia after adequate treatment with 1-month paliperidone palmitate extended-release (Invega Sustenna®) for at least four months. Dosage The dose of 3-month […]

Read More

03
Dec
2016
Paliperidone palmitate (Invega Sustenna®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Paliperidone palmitate (Invega Sustenna®) is an extended-release injectable second-generation (“atypical”) antipsychotic. Here is basic information about this medication. FDA-approved indications Treatment of schizophrenia Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants Dosage A. Schizophrenia Initiation (IM deltoid): Administer 234 mg […]

Read More

03
Dec
2016
Extended Release Olanzapine (Zyprexa Relprevv®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Extended Release Olanzapine (Zyprexa Relprevv®) is a long-acting, second-generation (atypical), injectable antipsychotic. Here is basic information about this medication. FDA-approved indications Schizophrenia Dosage Recommended dosing of extended release olanzapine based on correspondence to oral olanzapine doses A. First 8 weeks of treatment a) Target oral dose 10 mg/day: 210 […]

Read More


Page 12 of 24